Binding model for nonpeptide antagonists of αvβ3 integrin

被引:57
作者
Feuston, BP [1 ]
Culberson, JC
Duggan, ME
Hartman, GD
Leu, CT
Rodan, SB
机构
[1] Merck Res Labs, Dept Mol Syst, West Point, PA 19486 USA
[2] Merck Res Labs, Dept Med Chem, West Point, PA 19486 USA
[3] Merck Res Labs, Dept Bone Biol & Osteoporosis Res, West Point, PA 19486 USA
关键词
D O I
10.1021/JM0203130
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A binding model for nonpeptide antagonists of integrin alpha(v)beta(3) has been developed through docking analyses utilizing the MMFFs force field and the recently published crystal structure, 1JV2. Results of this docking study have led to the identification of a novel binding model for selective antagonists of alpha(v)beta(3) over alpha(IIb)beta(3) integrins. Four different chemical classes are shown to bind in a similar fashion providing a measure of confidence in the proposed model. All alpha(v)beta(3) and alpha(IIb)beta(3) antagonists have a basic nitrogen separated some distance from a carboxylic acid to mimic RGD. For the alpha(v)beta(3) antagonists under present consideration, these charged ends are separated by twelve bonds. The basic nitrogen of the active alpha(v)beta(3) ligands are shown to interact with D150 of or, and the ligands' carboxylie acid interact with R214 of beta(3) while adopting an extended conformation with minimal protein induced internal strain. In addition, an energetically, favorable interaction is found with all of the active alpha(v)beta(3) molecules with Y178 of alpha(v) when docked to the crystallographically determined structure. This novel interaction may be characterized as pi-pi stacking for the most active of the alpha(v)beta(3) selective antagonists. The proposed model is consistent with observed activity as well as mutagenicity and photoaffinity cross-linking studies of the alpha(v)beta(3) integrin.
引用
收藏
页码:5640 / 5648
页数:9
相关论文
共 38 条
[1]   Non-peptide glycoprotein IIb/IIIa inhibitors .17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists [J].
Askew, BC ;
Bednar, RA ;
Bednar, B ;
Claremon, DA ;
Cook, JJ ;
McIntyre, CJ ;
Hunt, CA ;
Gould, RJ ;
Lynch, RJ ;
Lynch, JJ ;
Gaul, SL ;
Stranieri, MT ;
Sitko, GR ;
Holahan, MA ;
Glass, JD ;
Hamill, T ;
Gorham, LM ;
Prueksaritanont, T ;
Baldwin, JJ ;
Hartman, GD .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (12) :1779-1788
[2]  
Badger AM, 2001, ARTHRITIS RHEUM-US, V44, P128, DOI 10.1002/1529-0131(200101)44:1<128::AID-ANR17>3.0.CO
[3]  
2-M
[4]  
BAJT ML, 1992, J BIOL CHEM, V267, P3789
[5]  
CHAMBERS TJ, 1986, BONE MINER, V1, P127
[6]  
CHARO IF, 1991, J BIOL CHEM, V266, P1415
[7]   Non-peptide αvβ3 antagonists.: Part 3:: Identification of potent RGD mimetics incorporating novel β-amino acids as aspartic acid replacements [J].
Coleman, PJ ;
Brashear, KM ;
Hunt, CA ;
Hoffman, WF ;
Hutchinson, JH ;
Breslin, MJ ;
McVean, CA ;
Askew, BC ;
Hartman, GD ;
Rodan, SB ;
Rodan, GA ;
Leu, CT ;
Prueksaritanont, T ;
Fernandez-Metzler, C ;
Ma, B ;
Libby, LA ;
Merkle, KM ;
Stump, GL ;
Wallace, AA ;
Lynch, JJ ;
Lynch, R ;
Duggan, ME .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (01) :31-34
[8]   Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics [J].
Coller, BS .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) :1467-1471
[9]   Antibody to beta(3) integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat [J].
Crippes, BA ;
Engleman, VW ;
Settle, SL ;
Delarco, J ;
Ornberg, RL ;
Helfrich, MH ;
Horton, MA ;
Nickols, GA .
ENDOCRINOLOGY, 1996, 137 (03) :918-924
[10]   Integrin antagonists [J].
Curley, GP ;
Blum, H ;
Humphries, MJ .
CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 56 (5-6) :427-441